• 中国精品科技期刊
  • 中国高校百佳科技期刊
  • 中国中文核心期刊
  • 中国科学引文数据库核心期刊
Advanced Search
CUI Tao, WU Weidang, CI Xiaoyan, LI Wei, GUO Chuanmin, XU Jing, YI Xiulin, LIU Changxiao. Evaluation of tolerance and pharmacodynamics of nano-micelle irinotecan formulation[J]. Journal of China Pharmaceutical University, 2019, 50(2): 175-179. DOI: 10.11665/j.issn.1000-5048.20190207
Citation: CUI Tao, WU Weidang, CI Xiaoyan, LI Wei, GUO Chuanmin, XU Jing, YI Xiulin, LIU Changxiao. Evaluation of tolerance and pharmacodynamics of nano-micelle irinotecan formulation[J]. Journal of China Pharmaceutical University, 2019, 50(2): 175-179. DOI: 10.11665/j.issn.1000-5048.20190207
shu

Evaluation of tolerance and pharmacodynamics of nano-micelle irinotecan formulation

More Information
    Graphical Abstract
    • Abstract
  • This study aimed to investigate the improvement of tolance and pharmacodynamics of nano-micelle irinotecan formulation compared with irinotecan hydrochloride injection(Campto). The toxic effects of the two formulations on colorectal cancer cells COLO205, HT-29, HCT-8 and SW480 were tested in vitro. COLO205 tumor-bearing mouse model was constructed. The two preparations were given via tail vein injection to investigate the maximum tolerance dose(MTD)of tumor-bearing mice to the two preparations, and then to explore the improvement of anti-tumor efficacy of nano-micelle irinotecan formulation near the MTD. The results showed that there was no significant difference in the inhibitory effect of the two formulations on the four colorectal cancer cells in vitro. The MTD of nano-micelle irinotecan formulation and Campto was 432. 0 and 276. 5 mg/m2 respectively. Both of the two formulations showed significant anti-tumor effect in vivo, and the relative tumor proliferation rate and tumor wet weight inhibition rate of nano-micelle irinotecan formulation at high dose(345. 6 mg/m2)were significantly better than those of Campto at two doses(177. 0 and 221. 2 mg/m2)(P< 0. 05).
    • FullText(HTML)
    • References (12)
  • [1]
    Di B,Feng F,Yu LJ,et al.Studies on related substances of irinotecan,a new anticancer drug [J].J China Pharm Univ(中国药科大学学报),1999,30(3):36-38.
    [2]
    Rino Y,Yukawa N,Sato T,et al.Phase Ⅱ study on the combination of irinotecan plus cisplatin as a second-line therapy in patients with advanced or recurrent gastric cancer[J].Mol Clin Oncol,2013,1(4):749-752.
    [3]
    Petrelli F,Inno A,Ghidini A,et al.Second line with oxaliplatin- or irinotecan-based chemotherapy for gemcitabine-pretreated pancreatic cancer:a systematic review [J].Eur J Cancer,2017,81:174-182.
    [4]
    Zhang H,Zhang Y,Wang C,et al.Clinical research on therapeutic effect of combined application of lobaplatin and irinotecan in treating recurrant small cell lung cancer[J].Pak J Pharm Sci,2018,31(5):2295-2298.
    [5]
    Crozier JA,Advani PP,LaPlant B,et al.N0436(Alliance):a phase II trial of irinotecan with cetuximab in patients with metastatic breast cancer previously exposed to anthracycline and/or taxane-containing therapy[J].Clin Breast Cancer,2016,16(1):23-30.
    [6]
    Shoji T,Takatori E,Omi H,et al.A phase II study of irinotecan and pegylated liposomal doxorubicin in platinum-resistant recurrent ovarian cancer(Tohoku Gynecologic Cancer Unit 104 study)[J].Cancer Chemother Pharmacol,2017,80(2):355-361.
    [7]
    Abou-Taleb HA,Koshiyama M,Matsumura N,et al.Clinical efficacy of neoadjuvant chemotherapy with irinotecan(CPT-11)and nedaplatin followed by radical hysterectomy for locally advanced cervical cancer[J].J Int Med Res,2016,44(2):346-356.
    [8]
    Femke M,de Man,Andrew KL,et al.Individualization of irinotecan treatment:a review of pharmacokinetics,pharmacodynamics,and pharmacogenetics[J].Clin Pharmacokinet,2018,57(10):1229-1254.
    [9]
    Maeda H, Fang J, Inutsuka T, et al. Vascular permeability enhancement in solid tumor:various factors,mechanisms involved and its implications[J].Inter Immunopharmacol,2003,3(3):319-328.
    [10]
    Matsumura Y,Maeda H.A new concept for macromolecular therapeutics in cancer chemotherapy:mechanism of tumoritropic accumulation of proteins and the antitumor agent smancs[J].Cancer Res,1986,46:6387-6392.
    [11]
    Greish K,Fang J,Inutsuka T,et al.Macromolecular therapeutics,Advantages and prospects with special emphasis on solid tumortargeting[J].Clin Pharmacokinet,2003,42(13):1089-1105.
    [12]
    China Food and Drug Administration.Technical guidelines for non-clinical research on cytotoxic antitumor drugs [J].Chin J New Drugs Clin Rem,2008,27(6):462-465.
    • Related Articles

  • Related Articles

    [1]ZHAO Xiujuan, YANG Hengli, WU Jinye, ZHENG Xiaoqi, ZHANG Yaoping, LIN Yuping, HU Chunyan. Synthesis and anti-inflammatory activity of three series of coumarin-based derivatives[J]. Journal of China Pharmaceutical University, 2025, 56(1): 40-48. DOI: 10.11665/j.issn.1000-5048.2024072101
    [2]SHEN Yunhong, CHEN Hongjie, MAO Zewei, HUANG Zhengxiao, HU Chunyan. Synthesis and antifungal evaluation of chalcone derivatives combined with fluconazole against drug-resistant Candida albicans[J]. Journal of China Pharmaceutical University, 2023, 54(5): 564-568. DOI: 10.11665/j.issn.1000-5048.2023041002
    [3]WANG Mengxiao, MA Lingman, LIU Hanhan, JIANG Meiling, DOU Jie, ZHOU Changlin. Effective antimicrobial activity of Cbf-14-2 against penicillin-resistant bacteria in vitro and in vivo[J]. Journal of China Pharmaceutical University, 2017, 48(4): 496-502. DOI: 10.11665/j.issn.1000-5048.20170416
    [4]TANG Yong, LIAO Shengrong, LI Jinsheng, LIU Yonghong. Design, synthesis and cytotoxic activities of fluorine-containing 2, 5-diketopiperazine derivatives[J]. Journal of China Pharmaceutical University, 2016, 47(4): 412-421. DOI: 10.11665/j.issn.1000-5048.20160405
    [5]ZHANG Qian, CHEN Cen, YANG Fengqing, XIA Zhining. Mechanism of agonist-induced platelet activation and research progress of anti-platelet drugs[J]. Journal of China Pharmaceutical University, 2014, 45(6): 632-648. DOI: 10.11665/j.issn.1000-5048.20140604
    [6]LI Bing, LI Bo, ZHOU Changlin. Progress on antimicrobial peptides against drug-resistant bacterial infection[J]. Journal of China Pharmaceutical University, 2014, 45(5): 580-586. DOI: 10.11665/j.issn.1000-5048.20140514
    [7]WU Mingming, FANG Lei, GOU Shaohua, CHEN Li. 以2-甲基-2-取代苯氧基丙酸为离去基团的铂(Ⅱ)配合物的合成、表征及细胞毒活性[J]. Journal of China Pharmaceutical University, 2013, 44(4): 303-306. DOI: 10.11665/j.issn.1000-5048.20130403
    [8]Advances in the research of anti-tuberculosis drugs[J]. Journal of China Pharmaceutical University, 2010, 41(4): 299-305.
    [9]MIAO You-pan, LI Ai-xiu, LIU Tao, WU Ke-zhu. Molecular designing strategies of anti-drug-resistant HIV-1 protease inhibitors[J]. Journal of China Pharmaceutical University, 2009, 40(3): 279-283.
    [10]Structure-Cytotoxic Activity Relationships of Diterpenoid Tanshinones from Salvias[J]. Journal of China Pharmaceutical University, 2002, (1): 8-14.

Catalog

    Get Citation
    PDF
    XML
    Article views (892) PDF downloads (1334) Cited by()
    Turn off MathJax
    Article Contents
    Abstract
    References
    Related Articles

    Copyright © Journal of China Pharmaceutical University苏ICP备12050101号-2

    Address：24 Tongjia Lane, Nanjing City, Jiangsu Province （210009）Tel: 025-83271566E-mail: xuebao@cpu.edu.cn

    Supported by: Beijing Renhe Information Technology Co., Ltd.  Baidu Analytics

    Total visits：302623

    /

    DownLoad:  Full-Size Img  PowerPoint
    Return
    Return